From Nasdaq: 2024-11-15 14:38:00

Merck has entered an exclusive licensing deal with LaNova Medicines for their PD-1xVEGF bispecific antibody candidate, LM-299, in a $2.7 billion agreement. The deal aims to diversify Merck’s revenue base, reducing dependence on Keytruda. LM-299 targets two proteins, PD-1 and VEGF, potentially offering a unique treatment for solid tumors.

In the race for cancer therapies, Summit Therapeutics leads with ivonescimab outperforming Keytruda in NSCLC patients. Merck’s LM-299 faces competition from SYN-2510 and BNT327, targeting PD-1/VEGF. All companies have in-licensed drugs from Chinese biotechs, signaling a shift in oncology pipelines towards bispecific antibodies.

With Merck’s shares down 9.8% YTD, the deal provides a growth opportunity beyond Keytruda. The successful development of LM-299 could reduce revenue reliance on a single product. Solar stocks are poised to skyrocket, with analysts predicting solar energy to dominate renewable energy expansion. Investors can capitalize on this trend by choosing the right stocks in the clean energy sector.



Read more at Nasdaq: Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy